Tubulis GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.tubulis.com
Clinical Trials
4
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)phase_1_2
1 (25.0%)First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorsHNSCCSCLCNSCLCTNBC - Triple-Negative Breast CancerCRC
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Tubulis GmbH
- Target Recruit Count
- 130
- Registration Number
- NCT06657222
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Miami, Miami, Florida, United States
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Tubulis GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT06303505
- Locations
- 🇺🇦
Arensia Exploratory Medicine, Kyiv, Ukraine
🇺🇸Christ Hospital, Cincinnati, Ohio, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
News
No news found